3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
1
Interventions
pembrolizumab
9
trastuzumab deruxtecan
5
trametinib
4
dabrafenib
4
zanubrutinib
3
nilotinib
3
fludarabine
3
Trastuzumab
3
Dexamethasone
3
Cyclophosphamide
3
tucatinib
2
tisagenlecleucel
2
selinexor
2
relatlimab
2
pemigatinib
2
larotrectinib
2
ipatasertib
2
erdafitinib
2
entrectinib
2
enfortumab vedotin
2
defactinib
2
daratumumab
2
blinatumomab
2
binimetinib
2
belzutifan
2
axicabtagene ciloleucel
2
atezolizumab
2
TIC10 compound
2
Sunitinib
2
Specimen Handling
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Has announcements
×
melflufen
×
Clear all
NCT02963493
2022-11-22
HORIZON
Oncopeptides AB
Phase 2
Completed
157 enrolled
26 charts
1 FDA